Ash Access Technology   Report issue

For profit Phase 3
Founded: Lafayette IN United States (1983)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2006
NCT00628680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

heparin (liquaemin) (1 trial)

sodium citrate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2